Kellerhals Carrard advised Swiss clinical-stage biotechnology company MoonLake Immunotherapeutics on its agreement with American venture lending specialist Hercules Capital for up to $500 million in non-dilutive capital, with an initial $75 million drawn at closing. Pursuant to